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Purpose: Nocturia is a highly prevalent and bothersome symptom that might
(spontaneously) resolve. However, longitudinal data are not available on the
incidence and resolution of nocturia assessed with frequency-volume charts. In
this study we determined the prevalence, incidence and resolution rates of
nocturia assessed by frequency-volume charts, and compared nocturnal voiding
frequency over time as assessed by frequency-volume charts and questionnaires.
Materials and Methods: A longitudinal, population based study was conducted
among 1,688 men 50 to 78 years old with followup rounds at 2.1, 4.2 and 6.5
years. Nocturnal voiding frequency was determined with frequency-volume
charts and, for comparison purposes, with a question from the International
Prostate Symptom Score. Nocturia was defined as nocturnal voiding frequency 2
or greater. Prevalence, incidence and resolution rates were also determined.
Results: At the 2.1-year followup the incidence rate was 23.9% and the resolution
rate was 36.7%. The incidence rate was highest in the oldest group (70 to 78
years) and lowest in the youngest (50 to 54 years), whereas the resolution rate
was highest in the group 55 to 59 years old and lowest in the oldest group.
Because of the high resolution rate, no reliable incidence rates can be calculated.
Despite fluctuation, the prevalence of nocturia increased with age and over time
(from 34.4% to 44.7% for the total group, p 0.05). Men who had a frequency-
volume chart–nocturnal voiding frequency less than International Prostate
Symptom Score–nocturnal voiding frequency (6% of the population) more often
had this later on.
Conclusions: In this population frequency-volume chart assessed nocturia shows
considerable fluctuation. Nevertheless, prevalence increases over time and with
increasing age. Men who once had frequency-volume chart–nocturnal voiding
frequency less than International Prostate Symptom Score–nocturnal voiding
frequency are more likely to have this again. Therefore, frequency-volume charts
as well as the International Prostate Symptom Score should be used when
evaluating nocturia.
Key Words: nocturia, prevalence, urinary tract physiological phenomena,
incidence, data collection
1956 www.jurology.comNOCTURIA is a condition for which termi-
nology was standardized by the ICS in
2002.1,2 It is reported that less than 2
voids each night seem to generate no
bother and that 2 or more voids give rise
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different definitions used in earlier stud-
ies and various ways of assessing NVF,
eg questionnaires or FVCs, a range of
prevalence rates have been reported.6,7
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ASSESSMENT OF NOCTURIA IN OLDER MEN BASED ON FREQUENCY-VOLUME CHARTS 1957Nevertheless, the prevalence of nocturia in community
dwelling older men increases with age. Furthermore,
nocturia is the most bothersome lower urinary tract
symptom.8,9
Longitudinal data on the course of nocturia in
community dwelling men are limited to TAMUS,
which showed fluctuation of nocturia in individuals
over time.3 The value of this information for daily
practice is uncertain for several reasons. TAMUS is
based on the DAN-PSS-1 questionnaire,10 which
fails to emphasize the important point of getting out
of bed to void at night and, therefore, does not com-
ply with the ICS definition of nocturia.2 In addition,
because of the DAN-PSS-1 response categories the
exact NVF could not be determined.11 It is also un-
clear whether fluctuation is an effect of the assess-
ment tool used. FVCs represent a different, possibly
more objective, method of assessing nocturia be-
cause no recall bias is involved.12 Furthermore, the
correlation between questionnaire data and FVCs is
only modest13 and, until now, no longitudinal data
have been available on FVC assessed nocturia.
Therefore, in this study we determine the preva-
lence, incidence and resolution rates of nocturia
based on FVCs in community dwelling older men.
The longitudinal relation between NVF as assessed
with FVCs and with questionnaires is also exam-
ined.
MATERIALS AND METHODS
The Krimpen study is a longitudinal study on urogenital
tract dysfunction and its impact on general health status.
The design of this institutional review board approved
study has been described elsewhere.13,14 All men age 50 to
78 years (reference date June 1995, sample size 3,924) in
the Dutch municipality Krimpen aan den IJssel were in-
vestigated. Exclusion criteria for participation were trans-
urethral or open prostatectomy, prostate or bladder can-
cer, neurogenic bladder disease, or negative advice from
their GP based on poor health (eg bedridden). At baseline
participants completed a 113-item questionnaire, includ-
ing the I-PSS, and visited the local GP health center for
medical examination. Then urological measurements
were performed at the urological outpatient department of
the Erasmus Medical Centre Rotterdam and participants
completed a 3-day FVC.
Followup
The followup rounds were performed after an average
interval of 2.1, 4.2 and 6.5 years.15 If the participant had
not died or moved away and no exclusion criteria were
met, the GPs were asked to send a re-invitation letter for
a first, second and third followup round. Men who had
undergone lower urinary tract surgery during followup
were censored. Additionally, for the third followup round
all nonresponders of the previous rounds were re-invited.Nocturia Determined From FVCs
On the 3-day FVC participants recorded each micturition
in 1-hour time units (first 2 days) and the volume of each
void (third day). Times of rising and bedtime were also
noted. Fluid intake was not recorded. Retrospectively this
complies with the 2002 ICS definition of a FVC.1
We determined the 24-hour voiding frequency from the
FVC. Since nocturia is defined as getting out of bed to void,
NVF was determined from bedtime to time of rising. This
method is more accurate than using fixed sleeping times,
which leads to significant misclassification of NVF.16 A
minimum of 4 recorded sleeping hours was required for
inclusion as an adequately completed FVC. NVF was es-
timated as the mean of 2 nights (when available) or the
frequency of 1 night to allow analyses of as many partic-
ipants as possible.
Nocturia, Incidence and Resolution
Nocturia was defined as a NVF of 2 or greater. Resolution
was defined as nocturia at baseline but no nocturia at
followup 1 (FU-1). The incidence rate was determined by
dividing the number of new cases of nocturia at FU-1 by
the total number of participants without nocturia at base-
line. The resolution rate was determined by dividing the
number of men who did not have nocturia at FU-1 by the
number of men who had nocturia at baseline.
Nocturia From I-PSS Questionnaire
We used the I-PSS nocturia question to determine I-PSS–
NVF. I-PSS–NVF and FVC–NVF were compared by sub-
tracting I-PSS-NVF from FVC-NVF. We defined scores of
1 or greater as FVC-NVF greater than I-PSS-NVF and
scores -1 or less as FVC-NVF less than I-PSS-NVF.
Statistical Analyses
All men were divided into 5-year age strata and their
general characteristics were noted. For each stratum the
prevalence rate for nocturia was determined and com-
pared throughout the FU rounds using McNemar’s test.
Incidence and resolution rates were also determined. Fi-
nally, the results of the FVCs were compared with I-PSS
data on nocturia to establish whether men had a higher or
lower estimated NVF. Statistical analyses were performed
with SPSS® version 15.0 with p 0.05 considered statis-
tically significant.
RESULTS
Baseline characteristics of the study population are
presented in table 1. Median patient age was 60.9
years (IQR 56.1–66.2). Most men (75.6%) had an
I-PSS of 7 or less. At baseline 1,597 men (95% of the
responders) completed a 3-day FVC. Because of
missing data on bedtime and time of rising (372),
and exclusion criteria (103), the NVF could be de-
termined in 1,122 men at baseline (71% of the com-
pleted charts). In terms of charts 701 (74%), 360
(76%) and 302 (76%) were used for analyses in the
followup rounds after 2.1 (FU-1), 4.2 (FU-2) and 6.5
years (FU-3), respectively. Scores on the I-PSS noc-
turia question did not differ between the men ex-
ASSESSMENT OF NOCTURIA IN OLDER MEN BASED ON FREQUENCY-VOLUME CHARTS1958cluded from study and those who provided exact
data on sleeping hours (p  0.251).
Table 2 shows the prevalence rates of nocturia (by
age strata) at baseline and followup. In the total
group the prevalence of nocturia increased signifi-
cantly over time from 34.4% at baseline to 44.7%
after 6.5 years (p 0.01). After 6.5 years there was a
significant increase in prevalence for all baseline age
strata except for 65 to 69 years old.
Table 3 presents nocturia incidence rates (in 464)
and resolution rates (in 237) after 2.1 years. The
overall incidence rate was 23.9% after 2.1 years. The
incidence was highest in the oldest group (70 to 78
years old) and lowest in the youngest group (50 to 54
years old). The overall resolution rate was 36.7%,
being highest in the youngest group and lowest in
the oldest group. The incidence rate was lower than
the resolution rate. However, since the absolute
number of men with incident nocturia was higher,
the prevalence rate increased over time.
The figure shows the pattern of incidence and
resolution of nocturia during followup. Of the men
with nocturia at baseline 36.7% did not have noctu-
ria after 2.1 years. Of the latter group 48.8% had
nocturia again after 4.2 years. Of the men who had
nocturia at baseline and after 2.1 years, 21.6% did
not have nocturia after 4.2 years. Thus, most men
Table 1. Baseline characteristics of study population






Median I-PSS (IQR) 4 (1–7)
No. I-PSS categories (%):
None (0) 113 (10.1)
Mild (1–7) 735 (65.5)
Moderate (8–19) 246 (21.9)
Severe (20–35) 28 (2.5)







Table 2. Prevalence of nocturia based on FVCs
Age Group Baseline % (95% CI) Followup 1 %
50–54 19.7 (14.3–25.1) 23.4 (15.8–
55–59 24.6 (19.7–29.5) 28.6 (22.1–
60–64 36.6 (30.8–42.4) 40.2 (32.9–
65–69 46.1 (39.3–52.8) 44.2 (35.8–
70–78 56.8 (48.3–65.4) 61.8 (50.7–
Overall 34.4 (31.6–37.2) 37.2 (33.7–* McNemar’s test compared to baseline, p 0.05.who did not have nocturia at baseline did not expe-
rience during 4.2 years of followup, and of those with
nocturia at baseline the majority still had nocturia
after 4.2 years.
Table 4 presents a comparison of the I-PSS and
FVC data. Of the 1,122 men who completed the FVC
and I-PSS at baseline, 33.3% reported a lower NVF
on FVCs, 60.3% scored an equal frequency and 6.3%
claimed a higher NVF on the I-PSS questionnaire
than on the FVC. A lower frequency on the I-PSS
nocturia question than on FVC was rarest in the
youngest age group. Of the men who had FVC-NVF
less than I-PSS-NVF at baseline 23.3% had this
again after 2.1 years. Men who made a correct esti-
mation or who had FVC-NVF greater than I-PSS-
NVF showed a similar pattern in the subsequent
followup. However, men who had FVC-NVF less
than I-PSS-NVF more often had FVC-NVF less than
I-PSS-NVF again in the subsequent followup. Over-
all, most men did not estimate I-PSS-NVF to be
higher than the recorded NVF on the FVC.
DISCUSSION
This study shows that the prevalence rate of noctu-
ria increases with age and over time, and that the
incidence and resolution rates are relatively high.
Because to our knowledge this is the first report on
FVC based longitudinal data on the prevalence, in-
cidence and resolution of nocturia, a direct compar-
ison with other studies is not possible.
TAMUS provided longitudinal data on nocturia
based on questionnaires (DAN-I-PSS-1).3 However,
the methodology of that study differs from ours in
) Followup 2 % (95% CI) Followup 3 % (95% CI)
39.0 (26.2–51.8)* 33.8 (22.3–45.4)*
33.0 (24.1–42.0) 34.8 (24.7–44.9)*
45.7 (35.5–56.0) 52.6 (41.2–64.1)*
60.9 (48.7–73.2) 58.7 (43.9–73.5)
55.9 (38.3–73.5) 60.9 (39.3–82.5)*
44.4 (39.3–49.6)* 44.7 (39.1–50.3)*




50–54 18.6 (10.7–26.4) 59.3 (39.5–79.1)
55–59 20.4 (13.7–27.1) 46.8 (32.0–61.6)
60–64 25.7 (17.5–33.8) 32.8 (20.7–44.9)
65–69 24.4 (14.6–34.1) 30.0 (18.1–41.9)
70–78 47.1 (29.4–64.7) 26.2 (12.3–40.1)







ASSESSMENT OF NOCTURIA IN OLDER MEN BASED ON FREQUENCY-VOLUME CHARTS 1959the 5 areas of 1) inclusion criteria—specific birth
years vs men in a specified age range, 2) followup
period—5 vs 2.1 years, 3) definition of nocturia—
categorized as mild (1 to 2 times), moderate (3 to 4)
or severe (5) vs NVF 2 or greater, 4) definition of
resolution—change from any DAN-PSS-1 symptom
category to a lower category vs change to NVF less
than 2, and 5) assessment tool used—questionnaire
Flowchart showing fluctuation of nocturia (defined as 2 or more
Asterisk indicates all men who completed FVC and did not mee
lost to followup, including men who moved out of area, did not re
sign indicates that number of men and prevalence rates do not co
men who did not complete FVC in previous rounds can be inclu
with reported sleeping hours.
Table 4. Consistency of under estimation, correct estimation
and overestimation of NVF, based on I-PSS nocturia question












Younger than 65 32.6 37.9 60.1 2.0
65 or Older 34.9 51.4 44.4 4.2
Overall 33.3 42.2 55.1 2.7
FVC-NVF  I-PSS-NVF:†
Younger than 65 59.9 27.1 67.6 5.4
65 or Older 61.4 28.2 65.6 6.1
Overall 60.3 27.4 67.0 5.6
FVC-NVF less than
I-PSS-NVF:‡
Younger than 65 7.5 21.2 51.5 27.3
65 or Older 3.7 50.0 40.0 10.0
Overall 6.3 27.9 48.8 23.3
* NVF was estimated lower on I-PSS than on FVC.
† NVF was estimated equally high on I-PSS as on FVC.
‡ NVF was estimated higher on I-PSS than on FVC.vs FVC. This rules out a straightforward compari-
son. Moreover the DAN-PSS-1 nocturia question,
“How many times do you have to urinate during the
night?” does not imply that one has to get up out of
bed to void.10 Thus, the DAN-PSS-1 does not concur
with the ICS definition of nocturia.2
In the Krimpen study the incidence rate of 23.9%
expressed in cases per 1,000 person-years, ie 129/
1,000 PY after 2.1 years, is considerably higher than
the TAMUS rate of 75/1,000 PY after 5 years. The
Krimpen study resolution rate is also considerably
higher than that in TAMUS (214/1,000 PY vs 35/
1,000 PY). The difference in incidence and resolution
might be explained by differences in the followup
period. In a 5-year period nocturia in an individual
might resolve but then become incident again (see
figure). Furthermore, epidemiological studies have
shown that a longer followup period can result in
lower incidence rates in diseases with a tendency to
resolve.17 The difference in resolution rate might be
due to the different response categories used in the
DAN-PSS-1. For example, most men have moderate
nocturia. Therefore, men who change from 2 voids to
1 void would be classified as resolved in our study,
but not in TAMUS where they would remain in the
same response category. Nevertheless, nocturia fluc-
tuates over time, and this fluctuation is independent
of the assessment method used. Moreover, this fluc-
tuation implies that it is almost impossible to calcu-
late reliable incidence rates. Preferably, future stud-
nal voids) in open population of older men as declared on FVCs.
sion criteria at baseline. Double asterisk indicates censored or
to re-invitation, were deceased or met exclusion criteria. Pound
ith numbers in flowchart per round because in prevalence rate,




ded wies should try to create a sample size sufficient for a
ASSESSMENT OF NOCTURIA IN OLDER MEN BASED ON FREQUENCY-VOLUME CHARTS1960focus on subgroups with more durable prevalence
and durable resolution of nocturia.
One limitation of the present study is that we
used exact sleeping hours to define the night,
thereby excluding some men from the analysis.
However, the scores on the I-PSS question of the
excluded men did not differ from those of men with
exact sleeping hour data. In addition, because the
oldest age groups had fewer men with missing data
on sleeping hours, this might have led to a slight
overestimation of the prevalence of nocturia in the
total population.
Resolution of nocturia might be due to medical
treatment. Although we did not conduct a phar-
macoepidemiological analysis, we believe that med-
ical treatment does not explain the fluctuation. Our
earlier study showed that only 9.5% of all partici-
pants sought medical help for LUTS.18 Of these par-
ticipants 3.1% received medical treatment, 2.6%
watchful waiting and 3.8% underwent surgical
treatment. Furthermore, treatment was not specifi-
cally focused on nocturia, and participants who un-
derwent prostate surgery were censored in the cur-
rent analyses. It has also been shown that nocturnal
voiding frequency as a symptom in men with benign
prostatic hyperplasia was reduced in only 13.9% of
these men, after the start of treatment with an
-blocker.19 In a similar study population equally
low medical treatment rates for lower urinary tract
symptoms were reported,20 reflecting the conserva-
tive prescription policy of Dutch GPs. The low treat-
ment rates also reflect the nature of our study, ie a
population based study rather than a (urological)
patient study. Therefore, it is highly unlikely that
medical therapy for benign prostatic hyperplasia
has a large mitigating effect on nocturia in our
study.
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